Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054992 | 0.87 | RAB9A (0.83) | RAB9APDE4BKDM4EMAPTKMT2A | |
| SCHEMBL2908596 | 0.84 | ALDH1A1 (0.69) | RAB9AKDM4EL3MBTL1NPC1MAPT | |
| SCHEMBL26102078 | 0.84 | CYP3A4 (0.58) | RAB9ADYRK1ACLK4L3MBTL1NPC1 | |
| SCHEMBL25414303 | 0.84 | RAB9A (0.64) | RAB9APDE4BKMT2AGAALTA4H | |
| SCHEMBL30520344 | 0.84 | RAB9A (0.64) | RAB9APDE4BKMT2AGAALTA4H | |
| SCHEMBL30520217 | 0.83 | RAB9A (0.63) | RAB9APDE4BKDM4ENPC1MAPT | |
| SCHEMBL19198137 | 0.83 | RAB9A (0.63) | RAB9APDE4BKDM4ENPC1MAPT | |
| SCHEMBL11078808 | 0.82 | SMN1; SMN2 (0.60) | RAB9APDE4BKDM4ENPC1MAPT | |
| SCHEMBL19198628 | 0.82 | RAB9A (1.00) | RAB9ACLK4KDM4EL3MBTL1NPC1 | |
| SCHEMBL5605226 | 0.82 | RAB9A (0.58) | RAB9AKDM4EL3MBTL1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052740-A1 | MODULATORS OF CIRCADIAN RHYTHMS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-02-16 | — | — | US | disclosed |
| US-11214542-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10807956-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10597365-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-10179769-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| CN-108976107-A | 3- aryl -4- alkoxybenzyl amine derivative and its preparation method and application | 南方医科大学 | 2018-12-11 | — | — | CN | disclosed |
| CN-107922338-A | The pyridine and application method being substituted | 艾伯维公司 | 2018-04-17 | — | — | CN | disclosed |
| US-20180044296-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9725441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
| US-11214542-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
| US-20230052740-A1 | MODULATORS OF CIRCADIAN RHYTHMS AND USES THEREOF | MTNR1A, PER2, MTNR1B | RAB9A 2858/4885PDE4B 448/4885DYRK1A 3680/4885 |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
| US-10179769-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
| US-10807956-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
| US-20180044296-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
| US-10597365-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | RAB9A 3032/4885PDE4B 346/4885DYRK1A 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.